

Serial No.: 08/471,474

IN THE CLAIMS:

Please cancel claims 1-6 and 22, and add the following new claims:

BB

--23. A purified HIV-1 variant virus,
wherein said HIV-1 variant virus differs genetically from the group of viruses
consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1% in Pol, and
13.0% in Env,
wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said
HIV-1 variant virus,
wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated
HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE
MICRO-ORGANISMES (CNCM) under No. I-641, and
wherein the genetic structure of said HIV-1 variant is the same as the genetic structure
of HIV-1.

24. The HIV-1 variant virus of claim 23, wherein the nucleic acid of said HIV-1
variant virus can be detected by hybridization with a DNA probe comprising the genomic
cDNA of HIV-1_{MAL}.

25. The HIV-1 variant virus of claim 23, wherein the nucleic acid of said HIV-1
variant virus can be detected by hybridization with a DNA probe comprising a restriction
enzyme fragment of the cDNA of HIV-1_{MAL}, and wherein the restriction enzyme is selected

Serial No.: 08/471,474

from the group consisting of *AvaI*, *BamHI*, *BglII*, *EcoRI*, *HincII*, *HindIII*, *KpnI*, *NdeI*, *PstI*, *SacI*, and *XbaI*.

26. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from the group of viruses consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1 % in Pol, and 13.0% in Env, and from HIV-1_{BRU} by at least 20.7% in Env,

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641.

27. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from the group of viruses consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1 % in Pol, and 13.0% in Env, and from HIV-1_{BRU} by at least 9.8 % in Gag,

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641.

Serial No.: 08/471,474

28. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from the group of viruses consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1 % in Pol, and 13.0% in Env, and from HIV-1_{BRU} by at least 5.5 % in Pol,

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641.

29. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from the group of viruses consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1 % in Pol, and 13.0% in Env, and from HIV-1_{BRU} by at least 9.8 % in Gag, 5.5% in Pol, and 20.7% in Env,

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641.

30. The HIV-1 variant virus of claim 29, wherein said HIV-1 variant virus differs genetically from HIV-1_{MAL} by 0-10.8% in Gag, 0%-8.4% in Pol, and 0%-19.8% in Env.

Serial No.: 08/471,474

31. The HIV-1 variant virus of claim 30, wherein said virus is HIV-1_{MAL}.

32. The HIV-1 variant virus of claim 30, wherein said virus is HIV-1_{ELI}.

33. The HIV-1 variant virus of any one of claims 26-30, wherein the nucleic acid of said HIV-1 variant virus can be detected by hybridization with a DNA probe selected from the group of nucleic acids consisting of the genomic cDNA of HIV-1_{MAL} and restriction enzyme fragments of the cDNA of HIV-1_{MAL}, and wherein the restriction enzyme is selected from the group consisting of *AvaI*, *BamHI*, *BglII*, *EcoRI*, *HincII*, *HindIII*, *KpnI*, *NdeI*, *PstI*, *SacI*, and *XbaI*.

34. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from HIV-1_{BRU} by at least 21.7% in Env,

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641.

35. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from the group of viruses consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1 % in Pol, and 13.0% in Env, and from HIV-1_{BRU} by at least 12.0 % in Gag,

Serial No.: 08/471,474

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641.

36. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from the group of viruses consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1 % in Pol, and 13.0% in Env, and from HIV-1_{BRU} by at least 7.7% in Pol,

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641.

37. A purified HIV-1 variant virus,

wherein said HIV-1 variant virus differs genetically from the group of viruses consisting of HIV-1_{IIIB}, HIV-1_{BRU}, and HIV-1_{ARV-2} greater than 3.4 % in Gag, 3.1 % in Pol, and 13.0% in Env, and from HIV-1_{BRU} by at least 9.8 % in Gag, 5.5% in Pol and 20.7% in Env,

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus, and